01—Abstract
Summary
Summary of the 10-K filed February 23, 2023. Cited figures are marked; the original filing is the authoritative source.
Thermo Fisher Scientific's FY2022 10-K shows a year of very large top-line growth driven by the PPD acquisition, offset by a sharp fall in COVID-19 testing demand and higher amortization.
Revenue rose 15% to $44.9 billiona, but organic revenue growth was roughly flat at 0%, because acquisitions contributed 18 points and currency translation subtracted 3 points (about $1.35 billion unfavorable). GAAP operating margin fell to 18.7% from 25.6%, and GAAP diluted EPS declined 9% to $17.63. Adjusted EPS fell 8% to $23.24, and adjusted operating margin dropped to 24.5% from 31.0%.
Management attributed the margin compression mainly to lower COVID-19 testing volume, strategic growth investments, and the dilution from recently acquired businesses, partly offset by pricing and productivity gains. COVID-19 product sales fell from $7.26 billion in 2021 to $3.11 billionb in 2022, and the Life Sciences Solutions and Specialty Diagnostics segments bore most of that decline. Growth came from Laboratory Products and Biopharma Services, where revenue rose 51% to $22.5 billion, largely from PPD's clinical research business, which contributed $7.11 billion.
Analytical Instruments grew organically on semiconductor and materials science demand. Free cash flow was steady at $6.9 billionc, and the company returned $3.0 billion through buybacks and $0.46 billion through dividends. It also repurchased another $3.0 billion early in 2023, leaving $1.0 billion of authorization available.
Balance sheet leverage remains significant. Total debt was $34.5 billiond against $8.5 billion of cash, and goodwill plus intangibles total about $58.6 billion, which keeps impairment risk and future amortization meaningful. The company guides to a 2023 GAAP effective tax rate of 7% to 9%, an adjusted rate of about 11%, and capital expenditures of about $2.0 billion.
02—Key points
Key Highlights
- Revenue grew 15% to $44.9 billion, but organic revenue growth was flat at 0%; acquisitions (mainly PPD) contributed 18 points and currency subtracted 3 points.
- GAAP operating margin fell to 18.7% from 25.6%, and adjusted operating margin fell to 24.5% from 31.0%, reflecting lower COVID-19 testing volume and growth investments.
- GAAP diluted EPS declined 9% to $17.63; adjusted EPS declined 8% to $23.24.
- COVID-19 testing product sales dropped to $3.11 billion from $7.26 billion, a major headwind concentrated in Life Sciences Solutions and Specialty Diagnostics.
- Laboratory Products and Biopharma Services revenue rose 51% to $22.5 billion, with PPD contributing $7.11 billion; segment income rose 56%.
- Free cash flow was $6.9 billion. Capital was returned via $3.0 billion of 2022 buybacks, another $3.0 billion repurchased in early 2023, and $0.46 billion in dividends.
- Total debt is $34.5 billion, and goodwill plus intangibles total roughly $58.6 billion, so leverage and impairment exposure remain key investor considerations.
03—One dollar
04—Financials
Financial Highlights
Figures from 10-KFY2022filed February 23, 2023Financial Statements
FY2022 against FY2021
| Line item | FY2022FY2021 | Change |
|---|---|---|
| Revenue | $44.91B$39.21B | +14.5% |
| R&D Expenses | $1.47B$1.41B | +4.6% |
| SG&A Expenses | $8.99B$8.01B | +12.3% |
| Operating Expenses | $36.52B$29.18B | +25.1% |
| Operating Income | $8.39B$10.03B | −16.3% |
| Interest Expense | $726.00M$536.00M | +35.4% |
| Net Income | $6.95B$7.72B | −10.0% |
| EPS (Basic) | $17.75$19.62 | −9.5% |
| EPS (Diluted) | $17.63$19.46 | −9.4% |
| Shares Outstanding (Basic) | 392.00M394.00M | −0.5% |
| Shares Outstanding (Diluted) | 394.00M397.00M | −0.8% |
05—Questions
Frequently Asked Questions
Why did GAAP operating margin decline so sharply in 2022?
The decline was driven mainly by lower high-margin COVID-19 testing volume, continued strategic growth investments, the dilution from lower-margin acquired businesses such as PPD, and higher amortization of acquisition-related intangibles ($2.40 billion in 2022 versus $1.76 billion in 2021). Strong pricing and productivity gains partly offset these pressures.
How much of the revenue growth was organic?
Essentially none. Reported revenue grew 15%, but organic growth was 0%. Acquisitions added about 18 points and currency translation reduced growth by about 3 points, with the U.S. dollar's strength costing $1.35 billion in revenue.
What is the company's capital allocation outlook?
Management says it deploys capital primarily through M&A and secondarily through share buybacks and dividends. In early 2023 it repurchased $3.0 billion of stock, leaving $1.0 billion of authorization at February 23, 2023. Expected 2023 capital expenditures are about $2.0 billion, and the company expects its 2023 GAAP tax rate to be 7% to 9%.
What are the main risks flagged for investors?
Key risks include the sustainability of COVID-19 testing and vaccine demand, significant debt of $34.5 billion with a 3.5x minimum interest coverage covenant, goodwill and intangible assets of about $58.6 billion that could be impaired, customer and government spending cycles, currency exposure from roughly half of cash being held outside the U.S., and product liability and regulatory compliance matters.
06—Continue